Alimetrics Ltd, Helsinki, Finland.
Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome
Article first published online: 29 MAY 2007
Alimentary Pharmacology & Therapeutics
Volume 26, Issue 3, pages 463–473, August 2007
How to Cite
KAJANDER, K., KROGIUS-KURIKKA, L., RINTTILÄ, T., KARJALAINEN, H., PALVA, A. and KORPELA, R. (2007), Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics, 26: 463–473. doi: 10.1111/j.1365-2036.2007.03391.x
- Issue published online: 29 MAY 2007
- Article first published online: 29 MAY 2007
- Publication data Submitted 25 April 2007 First decision 16 May 2007 Resubmitted 24 May 2007 Accepted 24 May 2007
Background A multispecies probiotic has shown beneficial effects in irritable bowel syndrome. In addition, certain other probiotics have demonstrated advantageous effects, but the mechanisms behind this are poorly understood.
Aim To investigate the mode of action of a multispecies probiotic consisting of Lactobacillus rhamnosus GG, Lactobacillus rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium breve Bb99 by monitoring its effects on intestinal microbiota and markers of microbial activity.
Methods A total of 55 irritable bowel syndrome patients participated in this placebo-controlled double-blind trial. Subjects received either multispecies probiotic or placebo supplementation daily during a 6-month period. The composition of intestinal microbiota was analysed with real-time polymerase chain reaction, short-chain fatty acids with gas chromatography and enzymes with spectrophotometer.
Results Each supplemented probiotic strain was detected in faecal samples. Intestinal microbiota remained stable during the trial, except for Bifidobacterium spp., which increased in the placebo group and decreased in the probiotic group (P = 0.028). No changes in short-chain fatty acids occurred. A decrease in ß-glucuronidase activity was detected in 67% of the subjects in the probiotic group vs. 38% in the placebo group (P = 0.06).
Conclusions Factors other than the microbial groups and metabolites studied herein seem responsible for the alleviation of irritable bowel syndrome symptoms by the multispecies probiotic.